Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.

Juliette BergerMarie ViganBruno PereiraThu Thuy NguyenRoseline FroissartNadia BelmatougFlorence DalbièsAgathe MasseauChristian RoseChristine SerratriceYves-Marie PersIvan BertchanskyFabrice CamouMonia BengherbiaCéline BourgneCatherine CaillaudMagali PettazzoniAmina BerrahalJérôme StirnemannFrance MentréMarc G Berger

Published in: Clinical pharmacokinetics (2020)

This study provides novel pharmacokinetic data that support current imiglucerase administration regimens and suggests the existence of a glucocerebrosidase activity threshold related to Gaucher disease type 1 aggressiveness. These findings can potentially improve Gaucher disease type 1 management algorithms and clinical decision making.

Keyphrases

replacement therapy
decision making
machine learning
dendritic cells
electronic health record
immune response
deep learning
big data
smoking cessation
drug induced